CTNM (Contineum Therapeutics) Other Stockholders Equity : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Other Stockholders Equity?

Contineum Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.00 Mil.

Contineum Therapeutics's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($-0.00 Mil) but then increased from Sep. 2024 ($-0.00 Mil) to Dec. 2024 ($0.00 Mil).

Contineum Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Contineum Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Other Stockholders Equity Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

Contineum Therapeutics Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial					-	-	-	-	-

Contineum Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Contineum Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.